Back to search results

Phase 2a Study of ALN-PNP for PNPLA3-Related MASLD

This study is testing ALN-PNP, a drug designed to reduce a protein (PNPLA3) in the liver that can contribute to fatty liver disease (Metabolic Dysfunction-Associated Steatotic Liver Disease or MASLD). Researchers want to see if ALN-PNP, given alone or with tirzepatide (a drug for blood sugar, appetite, and weight), can help lower liver fat. The study will measure changes in liver fat at 24 and 48 weeks. You might be able to join if you are 18-75 years old, have a specific genetic marker (PNPLA3 p.I148M genotype), have at least 15% liver fat, and a BMI between 30 and 45. The study's current status is unclear.

Study design
This is an interventional study planning to enroll 204 participants. It will compare ALN-PNP, tirzepatide, and a placebo (an inactive substance matching ALN-PNP).
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The study measures liver fat changes at 24 and 48 weeks, suggesting follow-up for at least 48 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07527910

A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD

Recruiting
PHASE2Ages 18–75InterventionalTreatment
Regeneron Pharmaceuticals
~204 participants
Updated 2026-08-10 on ClinicalTrials.gov
What's tested:ALN-PNPTirzepatidePlacebo

At a glance

Recruiting sites
6 of 6 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percent change in liver fat
Measured over From baseline at week 24
+1 more outcome measured

Conditions

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Explore related trials

Homozygous PNPLA3-Related MASLDNonalcoholic Fatty Liver DiseaseNonalcoholic SteatohepatitisPATATIN-LIKE PHOSPHOLIPASE DOMAIN-CONTAINING PROTEIN 3

NCT07527910

Where you'd take part

This study runs at 6 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Advanced Medical Trials

    Georgetown, Texasno site contact published

    Recruiting

  • American Research Corporation

    Austin, Texasno site contact published

    Recruiting

  • American Research Corporation at The Texas Liver Institute

    San Antonio, Texasno site contact published

    Recruiting

  • California Liver Research Institute

    Pasadena, Californiano site contact published

    Recruiting

  • Southern California Research Center

    Coronado, Californiano site contact published

    Recruiting

  • Tandem Clinical Research, Plaza II

    Metairie, Louisianano site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Clinical Trial Management · STUDY_DIRECTOR · Regeneron Pharmaceuticals

Who to contact

Clinical Trials Administrator
[email protected]
844-734-6643
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Percent change in liver fatFrom baseline at week 24

    Part A

  • Percent change in liver fatFrom baseline at week 48

    Part B